The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 16, 2021

Filed:

Sep. 13, 2019
Applicant:

Magenta Therapeutics Inc., Cambridge, MA (US);

Inventor:

Arthur Glenn Romero, Chesterfield, MO (US);

Assignee:

Magenta Therapeutics Inc., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 487/04 (2006.01); A61K 35/28 (2015.01); C07D 519/00 (2006.01); C07D 471/04 (2006.01); C12N 5/0789 (2010.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 35/28 (2013.01); C07D 471/04 (2013.01); C07D 519/00 (2013.01); C12N 5/0647 (2013.01); A61K 2035/124 (2013.01); C12N 2501/999 (2013.01); Y02A 50/401 (2018.01); Y02A 50/414 (2018.01);
Abstract

The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as methods of expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides methods of synthesizing aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells.


Find Patent Forward Citations

Loading…